New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

This Is Us star Chrissy Metz reflects on her struggles with her body image and self-worth, and shares her thoughts on weight ...

Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

Research carried out over the past year has shown a link between using GLP-1 medication for weight loss and a dangerous eye condition that results in sudden vision loss ...

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

The Hunting Wives' actress Chrissy Metz gets candid in a new cover story for PEOPLE on her thoughts about using weight loss ...

NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...